Cytokinetics Drug Patent Portfolio
Cytokinetics owns 1 orange book drug protected by 2 US patents Given below is the list of Cytokinetics's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12370179 | 15 Jul, 2042 | Active | |
| US10836755 | Cardiac Sarcomere Inhibitors | 18 Jan, 2039 | Active |
Latest Legal Activities on Cytokinetics's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Cytokinetics.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Initial letter Re: PTE Application to regulating agency | 06 Feb, 2026 | US10836755 |
| Patent Term Extension Application under 35 USC 156 Filed | 04 Feb, 2026 | US10836755 |
| Patent eCofC Notification | 18 Nov, 2025 | US12370179 |
| Email Notification | 18 Nov, 2025 | US12370179 |
| Recordation of Patent eCertificate of Correction | 18 Nov, 2025 | US12370179 |
| Mail Patent eCofC Notification | 18 Nov, 2025 | US12370179 |
| Post Issue Communication - Certificate of Correction | 29 Oct, 2025 | US12370179 |
| Recordation of Patent Grant Mailed | 05 Aug, 2025 | US12370179 |
| Patent Issue Date Used in PTA Calculation | 29 Jul, 2025 | US12370179 |
| Patent eGrant Notification | 29 Jul, 2025 | US12370179 |
| Email Notification | 29 Jul, 2025 | US12370179 |
| Mail Patent eGrant Notification | 29 Jul, 2025 | US12370179 |
| Recordation of Patent eGrant | 29 Jul, 2025 | US12370179 |
| Email Notification | 21 Jul, 2025 | US12370179 |
| Issue Notification Mailed | 16 Jul, 2025 | US12370179 |
Cytokinetics's Family Patents
Clinical Trials
Recent Clinical Trials by Cytokinetics:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy (nHCM) | Cytokinetics | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE3 |
| A Study to Evaluate the Effect of Aficamten in Pediatric Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM). | Cytokinetics | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE2, PHASE3 |
| Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM | Cytokinetics | NA |
COMPLETED
(Jun 1, 2026)
| PHASE3 |
Cytokinetics Drug List
Given below is the complete list of Cytokinetics's drugs and the patents protecting them.
1. Myqorzo
Myqorzo is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12370179 |
15 Jul, 2042
(15 years from now)
| Active | |
| US10836755 | Cardiac Sarcomere Inhibitors |
18 Jan, 2039
(12 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Myqorzo's drug page